Is Orforglipron (Foundayo) Safe While Breastfeeding?

Is orforglipron (Foundayo) safe while breastfeeding? Per its FDA-approved label on DailyMed, orforglipron is not recommended for nursing women — but the label frames this as a benefit-versus-need decision rather than an outright ban, and the human data behind it is thinner than you might expect. Here’s exactly what the label says, what the animal data does and doesn’t tell us, and where this fits alongside other GLP-1 medications.

What the FOUNDAYO label says about breastfeeding

Per DailyMed’s FOUNDAYO prescribing information, there are no data on the presence of orforglipron or its metabolites in human milk, on its effects on a breastfed infant, or on its effects on milk production. In other words: nobody has published human lactation data on this drug yet, because it’s newly approved.

In the absence of human data, the label points to an animal tissue distribution study: drug-related radioactivity was excreted into rat breast milk at concentrations roughly 3-fold higher than in the mother’s plasma. That’s an animal finding, not a human one, and it doesn’t tell us what actually happens in a nursing parent or infant. But it’s enough for the label to state plainly: Foundayo is not recommended for nursing women.

The label doesn’t stop there — it also says the decision should weigh the developmental and health benefits of breastfeeding against the mother’s clinical need for Foundayo, and any potential adverse effects on the breastfed child from the drug or from the underlying condition being treated. That’s a case-by-case clinical judgment, which is exactly why it belongs to you and your prescriber, not a general guide.

Human data vs. animal data: what’s actually known

Orforglipron and breastfeeding — human vs. animal data:

	What’s known
Presence in human milk	Unknown — no human data published
Effect on breastfed infant	Unknown — no human data published
Effect on milk production/supply	Unknown — no human data published
Animal data	Present in rat breast milk, ~3x plasma concentration (tissue distribution study)
Label recommendation	Not recommended for nursing women

Source: FOUNDAYO FDA label (DailyMed).

The gap between “animal data shows presence” and “we know what this means for a nursing infant” is real, and it’s worth naming rather than glossing over. Regulatory labels are conservative by design — when human data doesn’t exist, a positive finding in an animal model is generally enough to trigger a “not recommended” rather than a wait-and-see stance. That’s standard practice across the GLP-1 class, not something specific to orforglipron.

How this compares to other GLP-1s

GLP-1 and breastfeeding guidance follows a similar pattern across the drug class: limited or evolving human lactation data, not unique to orforglipron. If you’re comparing options, the injectable and oral semaglutide labels (Ozempic, Wegovy, Rybelsus) and the tirzepatide label (Mounjaro, Zepbound) each carry their own breastfeeding guidance — see the MedlinePlus pages linked below for what’s published on those specific drugs. The details differ by medication, so don’t assume orforglipron’s data applies to a different GLP-1, or vice versa. If you’re weighing orforglipron against semaglutide more broadly, Orforglipron vs Ozempic and Orforglipron vs Rybelsus cover the mechanism and administration differences.

This breastfeeding caution is separate from — but related to — the drug’s pregnancy warning. If you’re pregnant, planning a pregnancy, or recently postpartum, Is Orforglipron Safe During Pregnancy? covers the fetal-risk data and the label’s discontinue-on-recognition guidance in more depth.

What to consider if you’re breastfeeding and thinking about orforglipron

A few practical points, none of which substitute for a conversation with your care team:

• This is a “not recommended,” clinical-judgment decision, not a hard contraindication like pregnancy. The label’s own language leaves room for a prescriber to weigh your specific situation — how long you plan to nurse, your health needs, and the lack of human data — rather than issuing a blanket rule.
• Timing matters. If you started orforglipron before finding out you were nursing, or you’re considering starting it while breastfeeding, don’t make a unilateral call either way. Bring it to your prescriber or a lactation consultant promptly.
• The absence of data cuts both ways. No human data doesn’t mean “proven safe,” and it doesn’t mean “proven harmful” either — it means the honest answer is “unknown,” which is exactly why the label defaults to caution.
• Reproductive-potential guidance is a separate topic. If you’re also on hormonal birth control, orforglipron’s label has specific guidance on oral contraceptive absorption that’s distinct from the breastfeeding question — see Does Orforglipron Affect Birth Control? for that.

Questions worth bringing to your prescriber

If breastfeeding and orforglipron both apply to your situation, a short, specific conversation with your prescriber or a lactation consultant will get you further than searching for a general answer. Consider asking:

• Given how long I plan to breastfeed, does starting or continuing orforglipron make sense for me right now, or would it make more sense to wait?
• Are there non-drug approaches to weight management during lactation worth discussing first?
• If I’m already taking orforglipron and just found out I’m breastfeeding (or about to start), what’s the recommended next step?
• Is there anything about my specific health history that changes how this “not recommended” guidance applies to me?

None of these have a one-size-fits-all answer, which is precisely why the label leaves the call to a clinical judgment rather than a fixed rule.

Bottom line

The FOUNDAYO label states orforglipron is not recommended for nursing women, based on an absence of human lactation data and an animal study showing the drug concentrates in rat breast milk at about 3 times plasma levels. Whether that translates to any real effect on a human infant or on milk supply isn’t known — and that uncertainty, not a confirmed harm, is what drives the label’s caution. If you’re breastfeeding and considering orforglipron, or already taking it and didn’t realize this guidance existed, talk to your prescriber or a lactation consultant about your specific situation before making any change.

For more on how orforglipron works and who it’s approved for, see Foundayo (Orforglipron): A Simple Guide and Who Should Take Orforglipron?